Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 2

Status

Withdrawn 7Unknown 5Recruiting 3Completed 3Not yet recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 7

Study Type

Interventional 7

Sponsor

Cancer Type

Gastrointestinal 7

Conditions

Carcinoma, Hepatocellular 7Carcinoma, Non-Small-Cell Lung 3Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Turcot syndrome 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Melanoma 1Lung Neoplasms 1Lung Diseases 1Hemangiosarcoma 1Colorectal Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Sorafenib 13Radiosurgery 9spartalizumab 7lenvatinib 7Oxaliplatin 6Gemcitabine 5Fluorouracil 5Radiotherapy 4Cisplatin 4Bevacizumab 4atezolizumab 3Leucovorin 3Folfox protocol 3Doxorubicin 3gadolinium ethoxybenzyl DTPA 2fludarabine 2cabozantinib 2Nivolumab 2Mitomycin 2Electroporation 2Cyclophosphamide 2Chemoembolization, Therapeutic 2tremelimumab 1toripalimab 1tocilizumab 1tislelizumab 1temsirolimus 1tazemetostat 1sitravatinib 1pirarubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Hepatocellular × spartalizumab × Clear all
NCT03775707 2019-05-06

Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria

Sun Yat-sen University

Phase 2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT03780634 2019-05-06

HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC

Sun Yat-sen University

Phase 2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT03803254 2019-05-06

HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC

Sun Yat-sen University

Phase 2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT03744247 2019-05-02

Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC

Sun Yat-sen University

Phase 3 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT03782831 2019-05-02

TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC

Sun Yat-sen University

Phase 2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT03791918 2019-05-02

Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria

Sun Yat-sen University

Phase 3 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT03746249 2019-04-17

Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC

Sun Yat-sen University

Phase 2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡